Identification

Name
Drospirenone
Accession Number
DB01395
Type
Small Molecule
Groups
Approved
Description

Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. It was shown in animal studies that drospirenone exhibits antiandrogenic activity judging from accessory sex gland growth in castrated, androgen-treated, juvenile rats.

Structure
Thumb
Synonyms
  • 1,2-Dihydrospirorenone
  • 6beta,7Beta;15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
  • 6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone
  • Dehydrospirorenone
  • Drospirenona
  • Drospirenonum
  • DRSP
External IDs
ZK-30595
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AngeliqDrospirenone (.25 mg/1) + Estradiol (.5 mg/1)Tablet, film coatedOralBayer2012-02-29Not applicableUs
AngeliqDrospirenone (.5 mg/1) + Estradiol (1 mg/1)Tablet, film coatedOralBayer2005-11-28Not applicableUs
AngeliqDrospirenone (.5 mg/1) + Estradiol (1 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2010-09-29Not applicableUs
AngeliqDrospirenone (1.0 mg) + Estradiol (1.0 mg)TabletOralBayer2008-10-20Not applicableCanada
Drospirenone and ethinyl estradiolDrospirenone + Ethinyl EstradiolKitNivagen Pharmaceuticals, Inc.2017-08-15Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitMylan Pharmaceuticals2015-08-28Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitOralPharmaceutics International, Inc. (Pii)2017-10-26Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitGlenmark Pharmaceuticals Inc.,Usa2015-08-17Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitA S Medication Solutions2016-03-252017-06-20Us
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitNivagen Pharmaceuticals, Inc.2017-08-16Not applicableUs
Categories
UNII
N295J34A25
CAS number
67392-87-4
Weight
Average: 366.4932
Monoisotopic: 366.219494826
Chemical Formula
C24H30O3
InChI Key
METQSPRSQINEEU-HXCATZOESA-N
InChI
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
IUPAC Name
(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁹.0¹⁶,¹⁸]nonadecane-15,2'-oxolan]-5-ene-5',7-dione
SMILES

Pharmacology

Indication

For the prevention of pregnancy in women who elect an oral contraceptive.

Structured Indications
Pharmacodynamics

Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.

Mechanism of action

Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

TargetActionsOrganism
AProgesterone receptor
agonist
Human
AMineralocorticoid receptor
antagonist
Human
AAndrogen receptor
antagonist
Human
Absorption

Oral bioavailability is approximately 76%.

Volume of distribution
Not Available
Protein binding

95-97%

Metabolism

Extensively metabolized following oral or intravenous administration. The two major metabolites are inactive and are formed independent of the CYP450 enzyme system. The metabolites are the acid form of drospirenone formed by opening of the lactone ring and the 4,5-dihydro-drospirenone-3-sulfate.

Route of elimination
Not Available
Half life

30 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Drospirenone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Drospirenone.Approved, Investigational
AceclofenacAceclofenac may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
AcemetacinAcemetacin may increase the hyperkalemic activities of Drospirenone.Approved
AcenocoumarolDrospirenone may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
AcitretinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Acitretin.Approved
AdapaleneAdapalene may increase the hyperkalemic activities of Drospirenone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Drospirenone.Experimental, Investigational
AlclofenacAlclofenac may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Drospirenone.Approved, Illicit
AliskirenDrospirenone may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AlitretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Alitretinoin.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Drospirenone.Investigational
AlminoprofenAlminoprofen may increase the hyperkalemic activities of Drospirenone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Drospirenone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Drospirenone.Illicit
AmilorideDrospirenone may increase the hyperkalemic activities of Amiloride.Approved
AmiodaroneThe serum concentration of Drospirenone can be increased when it is combined with Amiodarone.Approved, Investigational
AmobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Amobarbital.Approved, Illicit
AndrographolideAndrographolide may increase the hyperkalemic activities of Drospirenone.Investigational
AnisodamineAnisodamine may increase the hyperkalemic activities of Drospirenone.Investigational
AntipyrineAntipyrine may increase the hyperkalemic activities of Drospirenone.Approved
ApocyninApocynin may increase the hyperkalemic activities of Drospirenone.Investigational
ApremilastApremilast may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
AprepitantThe serum concentration of Drospirenone can be decreased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Drospirenone.Approved, Investigational
ArtemetherThe serum concentration of Drospirenone can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Drospirenone can be increased when it is combined with Atazanavir.Approved, Investigational
AzapropazoneAzapropazone may increase the hyperkalemic activities of Drospirenone.Withdrawn
AzelastineAzelastine may increase the hyperkalemic activities of Drospirenone.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Drospirenone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Drospirenone.Investigational
BalsalazideBalsalazide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
BarbexacloneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Drospirenone.Investigational
BenazeprilBenazepril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
BendazacBendazac may increase the hyperkalemic activities of Drospirenone.Experimental
BenorilateBenorilate may increase the hyperkalemic activities of Drospirenone.Experimental
BenoxaprofenBenoxaprofen may increase the hyperkalemic activities of Drospirenone.Withdrawn
BevoniumBevonium may increase the hyperkalemic activities of Drospirenone.Experimental
BexaroteneThe serum concentration of Drospirenone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Drospirenone.Experimental, Illicit, Withdrawn
BoceprevirThe serum concentration of Drospirenone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Drospirenone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacBromfenac may increase the hyperkalemic activities of Drospirenone.Approved
BucillamineBucillamine may increase the hyperkalemic activities of Drospirenone.Investigational
BufexamacBufexamac may increase the hyperkalemic activities of Drospirenone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
BumadizoneBumadizone may increase the hyperkalemic activities of Drospirenone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Drospirenone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drospirenone.Approved, Illicit, Vet Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.Approved
Candesartan cilexetilCandesartan may increase the hyperkalemic activities of Drospirenone.Approved
CandoxatrilCandoxatril may increase the hyperkalemic activities of Drospirenone.Experimental
CaptoprilCaptopril may increase the hyperkalemic activities of Drospirenone.Approved
CarbamazepineThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Drospirenone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Drospirenone.Illicit, Investigational, Vet Approved
CarprofenCarprofen may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the hyperkalemic activities of Drospirenone.Experimental
CelecoxibCelecoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
CeritinibThe serum concentration of Drospirenone can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.Approved
CholestyramineThe serum concentration of Drospirenone can be decreased when it is combined with Cholestyramine.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the hyperkalemic activities of Drospirenone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Drospirenone.Experimental
CilazaprilCilazapril may increase the hyperkalemic activities of Drospirenone.Approved
ClarithromycinThe serum concentration of Drospirenone can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Drospirenone can be decreased when it is combined with Clobazam.Approved, Illicit
ClonixinClonixin may increase the hyperkalemic activities of Drospirenone.Approved
ClorindioneDrospirenone may decrease the anticoagulant activities of Clorindione.Experimental
CobicistatThe serum concentration of Drospirenone can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Drospirenone.Approved, Illicit
ColesevelamThe serum concentration of Drospirenone can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Drospirenone can be decreased when it is combined with Colestipol.Approved
CurcuminCurcumin may increase the hyperkalemic activities of Drospirenone.Investigational
D-LimoneneD-Limonene may increase the hyperkalemic activities of Drospirenone.Investigational
DabrafenibThe serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Drospirenone can be decreased when it is combined with Darunavir.Approved
DelaprilDelapril may increase the hyperkalemic activities of Drospirenone.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Drospirenone.Investigational
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Drospirenone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drospirenone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Drospirenone.Approved, Investigational
DiclofenacDiclofenac may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
DicoumarolDrospirenone may decrease the anticoagulant activities of Dicoumarol.Approved
DifenpiramideDifenpiramide may increase the hyperkalemic activities of Drospirenone.Experimental
DiflunisalDiflunisal may increase the hyperkalemic activities of Drospirenone.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drospirenone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drospirenone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Drospirenone.Experimental, Illicit
DiphenadioneDrospirenone may decrease the anticoagulant activities of Diphenadione.Experimental
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drospirenone.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Drospirenone.Investigational
DroxicamDroxicam may increase the hyperkalemic activities of Drospirenone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Drospirenone.Approved
DuvelisibDuvelisib may increase the hyperkalemic activities of Drospirenone.Investigational
E-6201E-6201 may increase the hyperkalemic activities of Drospirenone.Investigational
EfavirenzThe serum concentration of Drospirenone can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Drospirenone.Approved
EnalaprilEnalapril may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hyperkalemic activities of Drospirenone.Approved
EpirizoleEpirizole may increase the hyperkalemic activities of Drospirenone.Approved
EplerenoneDrospirenone may increase the hyperkalemic activities of Eplerenone.Approved
EprosartanEprosartan may increase the hyperkalemic activities of Drospirenone.Approved
Eslicarbazepine acetateThe serum concentration of Drospirenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtanerceptEtanercept may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EthenzamideEthenzamide may increase the hyperkalemic activities of Drospirenone.Experimental
Ethyl biscoumacetateDrospirenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drospirenone.Approved, Illicit
EtodolacEtodolac may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EtoricoxibEtoricoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Drospirenone.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
ExenatideThe serum concentration of Drospirenone can be decreased when it is combined with Exenatide.Approved, Investigational
exisulindexisulind may increase the hyperkalemic activities of Drospirenone.Investigational
FelbamateThe serum concentration of Drospirenone can be decreased when it is combined with Felbamate.Approved
FelbinacFelbinac may increase the hyperkalemic activities of Drospirenone.Experimental
FenbufenFenbufen may increase the hyperkalemic activities of Drospirenone.Approved
FenoprofenFenoprofen may increase the hyperkalemic activities of Drospirenone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Drospirenone.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the hyperkalemic activities of Drospirenone.Experimental
FeprazoneFeprazone may increase the hyperkalemic activities of Drospirenone.Experimental
Ferulic acidFerulic acid may increase the hyperkalemic activities of Drospirenone.Experimental
FimasartanFimasartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Drospirenone.Approved
FloctafenineFloctafenine may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
FluindioneDrospirenone may decrease the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the hyperkalemic activities of Drospirenone.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the hyperkalemic activities of Drospirenone.Experimental
FlurbiprofenFlurbiprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Drospirenone.Experimental
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Drospirenone resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Drospirenone can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hyperkalemic activities of Drospirenone.Approved
FosphenytoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Fosphenytoin.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Drospirenone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Drospirenone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Drospirenone.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Drospirenone.Approved
GriseofulvinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GuacetisalGuacetisal may increase the hyperkalemic activities of Drospirenone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Drospirenone.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Drospirenone.Approved, Illicit, Investigational
HexobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Hexobarbital.Approved
HigenamineHigenamine may increase the hyperkalemic activities of Drospirenone.Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone.Approved, Illicit
IbuprofenIbuprofen may increase the hyperkalemic activities of Drospirenone.Approved
IbuproxamIbuproxam may increase the hyperkalemic activities of Drospirenone.Withdrawn
IcatibantIcatibant may increase the hyperkalemic activities of Drospirenone.Approved
IdelalisibThe serum concentration of Drospirenone can be increased when it is combined with Idelalisib.Approved
ImidaprilImidapril may increase the hyperkalemic activities of Drospirenone.Investigational
Imidazole salicylateImidazole salicylate may increase the hyperkalemic activities of Drospirenone.Experimental
IndinavirThe serum concentration of Drospirenone can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the hyperkalemic activities of Drospirenone.Investigational
IndomethacinIndomethacin may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
IndoprofenIndoprofen may increase the hyperkalemic activities of Drospirenone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Drospirenone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Drospirenone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Drospirenone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Drospirenone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Drospirenone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Drospirenone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Drospirenone.Approved
IrbesartanIrbesartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
IsotretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Isotretinoin.Approved
IsoxicamIsoxicam may increase the hyperkalemic activities of Drospirenone.Withdrawn
ItraconazoleThe serum concentration of Drospirenone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneKebuzone may increase the hyperkalemic activities of Drospirenone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Drospirenone.Approved, Investigational
KetoconazoleThe serum concentration of Drospirenone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
KetorolacKetorolac may increase the hyperkalemic activities of Drospirenone.Approved
LamotrigineThe serum concentration of Drospirenone can be decreased when it is combined with Lamotrigine.Approved, Investigational
LeflunomideLeflunomide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drospirenone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drospirenone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Drospirenone.Approved
LisinoprilLisinopril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LisofyllineLisofylline may increase the hyperkalemic activities of Drospirenone.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Drospirenone.Illicit
LonazolacLonazolac may increase the hyperkalemic activities of Drospirenone.Experimental
LopinavirThe serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LosartanLosartan may increase the hyperkalemic activities of Drospirenone.Approved
LoxoprofenLoxoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LumacaftorThe serum concentration of Drospirenone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the hyperkalemic activities of Drospirenone.Approved
MasoprocolMasoprocol may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
Mefenamic acidMefenamic acid may increase the hyperkalemic activities of Drospirenone.Approved
MeloxicamMeloxicam may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Drospirenone.Experimental
MesalazineMesalazine may increase the hyperkalemic activities of Drospirenone.Approved
MetamizoleMetamizole may increase the hyperkalemic activities of Drospirenone.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Drospirenone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Drospirenone.Approved, Illicit
MethohexitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methylphenobarbital.Approved
MetreleptinThe serum concentration of Drospirenone can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Drospirenone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Drospirenone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
MizoribineMizoribine may increase the hyperkalemic activities of Drospirenone.Investigational
MoexiprilMoexipril may increase the hyperkalemic activities of Drospirenone.Approved
MofebutazoneMofebutazone may increase the hyperkalemic activities of Drospirenone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Drospirenone.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Mycophenolic acidThe serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.Approved
NabumetoneNabumetone may increase the hyperkalemic activities of Drospirenone.Approved
NafamostatNafamostat may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
NaftifineNaftifine may increase the hyperkalemic activities of Drospirenone.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drospirenone.Approved
NaproxenNaproxen may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
NefazodoneThe serum concentration of Drospirenone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir.Approved
NepafenacNepafenac may increase the hyperkalemic activities of Drospirenone.Approved
NevirapineThe serum concentration of Drospirenone can be decreased when it is combined with Nevirapine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Drospirenone.Experimental
NifenazoneNifenazone may increase the hyperkalemic activities of Drospirenone.Experimental
Niflumic AcidNiflumic Acid may increase the hyperkalemic activities of Drospirenone.Approved
NimesulideNimesulide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the hyperkalemic activities of Drospirenone.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Drospirenone.Approved, Illicit
OlmesartanOlmesartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
OlopatadineOlopatadine may increase the hyperkalemic activities of Drospirenone.Approved
OlsalazineOlsalazine may increase the hyperkalemic activities of Drospirenone.Approved
OmapatrilatOmapatrilat may increase the hyperkalemic activities of Drospirenone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Drospirenone.Approved, Illicit
OrgoteinOrgotein may increase the hyperkalemic activities of Drospirenone.Vet Approved
OxaprozinOxaprozin may increase the hyperkalemic activities of Drospirenone.Approved
OxcarbazepineThe serum concentration of Drospirenone can be decreased when it is combined with Oxcarbazepine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drospirenone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Drospirenone.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
ParecoxibParecoxib may increase the hyperkalemic activities of Drospirenone.Approved
ParthenolideParthenolide may increase the hyperkalemic activities of Drospirenone.Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.Approved, Vet Approved
PentobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Drospirenone can be decreased when it is combined with Perampanel.Approved
PerindoprilPerindopril may increase the hyperkalemic activities of Drospirenone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Drospirenone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Drospirenone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Drospirenone.Approved, Investigational, Withdrawn
PhenindioneDrospirenone may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Drospirenone.Experimental
PhenprocoumonDrospirenone may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
PhenytoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone.Approved, Investigational
PirfenidonePirfenidone may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Drospirenone.Investigational
PiroxicamPiroxicam may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PirprofenPirprofen may increase the hyperkalemic activities of Drospirenone.Experimental
PosaconazoleThe serum concentration of Drospirenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Drospirenone.Approved, Investigational
PranoprofenPranoprofen may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
PrimidoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Primidone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the hyperkalemic activities of Drospirenone.Experimental
PropacetamolPropacetamol may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PropyphenazonePropyphenazone may increase the hyperkalemic activities of Drospirenone.Experimental
ProquazoneProquazone may increase the hyperkalemic activities of Drospirenone.Experimental
PrucaloprideThe serum concentration of Drospirenone can be decreased when it is combined with Prucalopride.Approved
PTC299PTC299 may increase the hyperkalemic activities of Drospirenone.Investigational
QuinaprilQuinapril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
RamiprilRamipril may increase the hyperkalemic activities of Drospirenone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drospirenone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
RescinnamineRescinnamine may increase the hyperkalemic activities of Drospirenone.Approved
ResveratrolResveratrol may increase the hyperkalemic activities of Drospirenone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Drospirenone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Drospirenone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Drospirenone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Drospirenone can be increased when it is combined with Ritonavir.Approved, Investigational
RofecoxibRofecoxib may increase the hyperkalemic activities of Drospirenone.Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Drospirenone.Approved, Investigational
SacubitrilSacubitril may increase the hyperkalemic activities of Drospirenone.Approved
SalicylamideSalicylamide may increase the hyperkalemic activities of Drospirenone.Approved
Salicylic acidSalicylic acid may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
SalsalateSalsalate may increase the hyperkalemic activities of Drospirenone.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Drospirenone.Experimental
SaquinavirThe serum concentration of Drospirenone can be decreased when it is combined with Saquinavir.Approved, Investigational
SaralasinSaralasin may increase the hyperkalemic activities of Drospirenone.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Drospirenone.Approved
SecobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Drospirenone.Approved, Investigational, Vet Approved
SemapimodSemapimod may increase the hyperkalemic activities of Drospirenone.Investigational
SeratrodastSeratrodast may increase the hyperkalemic activities of Drospirenone.Approved
SerrapeptaseSerrapeptase may increase the hyperkalemic activities of Drospirenone.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Drospirenone.Approved, Investigational
Sodium phosphateDrospirenone may increase the nephrotoxic activities of Sodium phosphate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Drospirenone.Investigational
SpiraprilSpirapril may increase the hyperkalemic activities of Drospirenone.Approved
SpironolactoneDrospirenone may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the hyperkalemic activities of Drospirenone.Investigational
St. John's WortThe therapeutic efficacy of Drospirenone can be decreased when used in combination with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Drospirenone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.Approved, Investigational
SugammadexThe serum concentration of Drospirenone can be decreased when it is combined with Sugammadex.Approved
SulfasalazineSulfasalazine may increase the hyperkalemic activities of Drospirenone.Approved
SulindacSulindac may increase the hyperkalemic activities of Drospirenone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Drospirenone.Approved, Investigational
SuprofenSuprofen may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the hyperkalemic activities of Drospirenone.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Drospirenone.Approved
TarenflurbilTarenflurbil may increase the hyperkalemic activities of Drospirenone.Investigational
TasosartanTasosartan may increase the hyperkalemic activities of Drospirenone.Approved
TelaprevirThe serum concentration of Drospirenone can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Drospirenone can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
TemocaprilTemocapril may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
TenidapTenidap may increase the hyperkalemic activities of Drospirenone.Experimental
TenoxicamTenoxicam may increase the hyperkalemic activities of Drospirenone.Approved
TepoxalinTepoxalin may increase the hyperkalemic activities of Drospirenone.Vet Approved
TeriflunomideTeriflunomide may increase the hyperkalemic activities of Drospirenone.Approved
ThalidomideDrospirenone may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiopental.Approved, Vet Approved
Tiaprofenic acidTiaprofenic acid may increase the hyperkalemic activities of Drospirenone.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Drospirenone.Experimental
TinoridineTinoridine may increase the hyperkalemic activities of Drospirenone.Investigational
TioclomarolDrospirenone may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Drospirenone can be increased when it is combined with Tipranavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Drospirenone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Drospirenone.Approved
Tolfenamic AcidTolfenamic Acid may increase the hyperkalemic activities of Drospirenone.Approved
TolmetinTolmetin may increase the hyperkalemic activities of Drospirenone.Approved
TopiramateThe serum concentration of Drospirenone can be decreased when it is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Drospirenone.Approved, Investigational
TrandolaprilTrandolapril may increase the hyperkalemic activities of Drospirenone.Approved
Tranexamic AcidDrospirenone may increase the thrombogenic activities of Tranexamic Acid.Approved
TranilastTranilast may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
TretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneDrospirenone may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the hyperkalemic activities of Drospirenone.Experimental
TriptolideTriptolide may increase the hyperkalemic activities of Drospirenone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
ValdecoxibValdecoxib may increase the hyperkalemic activities of Drospirenone.Investigational, Withdrawn
ValsartanValsartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Drospirenone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Drospirenone.Approved, Investigational
VoriconazoleThe serum concentration of Drospirenone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDrospirenone may decrease the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
ZileutonZileuton may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
ZofenoprilZofenopril may increase the hyperkalemic activities of Drospirenone.Experimental
ZomepiracZomepirac may increase the hyperkalemic activities of Drospirenone.Withdrawn
Food Interactions
  • Food reduces the rate of absorption, but not the extent of absorption.

References

Synthesis Reference

DOI: 10.1002/cjoc.201201147

General References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Wichianpitaya J, Taneepanichskul S: A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int. 2013;2013:487143. doi: 10.1155/2013/487143. Epub 2013 Feb 20. [PubMed:23577032]
External Links
Human Metabolome Database
HMDB15467
KEGG Drug
D03917
PubChem Compound
68873
PubChem Substance
46507653
ChemSpider
62105
ChEBI
50838
ChEMBL
CHEMBL1509
Therapeutic Targets Database
DAP001206
PharmGKB
PA164749409
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Drospirenone
ATC Codes
G03FA17 — Drospirenone and estrogenG03AC10 — DrospirenoneG03AA12 — Drospirenone and ethinylestradiol
FDA label
Download (292 KB)
MSDS
Download (567 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareEndometriosis of Uterus1
1CompletedNot AvailableHealthy Volunteers2
1CompletedOtherContraception1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentContraception2
1RecruitingOtherHealthy Volunteers1
1TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPolycystic Ovaries Syndrome1
1, 2Active Not RecruitingPreventionContraception / Hemostasis Parameter / Liver Metabolism1
2CompletedPreventionContraception1
2CompletedTreatmentHypertensive / One to five years postmenopausal / Pre-Hypertension1
2CompletedTreatmentOral Contraceptives (OC)1
2RecruitingPreventionPrevention of Pregnancy1
2TerminatedTreatmentDepressive State / PMDD / Premenstrual Dysphoric Disorder / Premenstrual Syndrome1
2TerminatedTreatmentHidradenitis Suppurativa (HS)1
3Active Not RecruitingPreventionContraception2
3Active Not RecruitingTreatmentContraception2
3CompletedPreventionContraception8
3CompletedPreventionContraception / Neural Tube Defects (NTDs) / Oral Contraceptives (OC)1
3CompletedPreventionContraception / Oral Contraceptives (OC) / Ovulation Inhibition1
3CompletedTreatmentAcne Vulgaris4
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentEndometriosis1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypertensive / One to five years postmenopausal1
3CompletedTreatmentOral Contraceptives (OC)1
3CompletedTreatmentPolycystic Ovaries Syndrome2
3CompletedTreatmentPremenstrual Dysphoric Disorder ( PMDD)1
3CompletedTreatmentPremenstrual Syndrome1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentVasomotor Symptoms2
3Unknown StatusNot AvailableContraceptive Affecting Blood Pressure / Contraceptive Affecting the Autonomic Nervous System1
3WithdrawnNot AvailableMetrorrhagia1
3WithdrawnTreatmentContraception1
3WithdrawnTreatmentDysmenorrhea1
4CompletedNot AvailableBlood Pressures / Contraception1
4CompletedNot AvailableContraception2
4CompletedBasic ScienceAdverse Effect of Oral Contraceptives, Subsequent Encounter1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentPolycystic Ovaries Syndrome1
4CompletedTreatmentPremenstrual Dysphoric Disorder1
4CompletedTreatmentPremenstrual Syndrome1
4CompletedTreatmentPrimary Dysmenorrhoea1
4CompletedTreatmentOne to five years postmenopausal1
4Enrolling by InvitationTreatmentBody Weight Changes1
4RecruitingTreatmentContraception1
4Unknown StatusNot AvailableDysmenorrhea / Endometriotic Cysts / Painful Intercourse / Pelvic Pain1
4Unknown StatusPreventionHyperandrogenism / Menstrual Irregularities / Polycystic Ovarian Syndrome1
4Unknown StatusTreatmentContraceptive Methods Comparison1
Not AvailableActive Not RecruitingNot AvailableDysmenorrhea1
Not AvailableCompletedNot AvailableAcne / Contraception / Premenstrual Syndrome1
Not AvailableCompletedNot AvailableContraception4
Not AvailableCompletedNot AvailableMetabolic Syndromes / Polycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailablePostmenopausal Osteoporosis (PMO) / Postmenopausal Period1
Not AvailableCompletedTreatmentDepressive State / Premenstrual Syndrome1
Not AvailableCompletedTreatmentEstro-progestin Drugs / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentOne to five years postmenopausal1
Not AvailableNot Yet RecruitingTreatmentPremature Menopause / Primary Ovarian Insufficiency1
Not AvailableRecruitingNot AvailableInfertilities1
Not AvailableUnknown StatusTreatmentEndothelial Dysfunction / Polycystic Ovaries Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Kit
TabletOral
KitOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6787531No2000-08-312020-08-31Us
US6933395No1997-08-112017-08-11Us
US8906890No2011-10-222031-10-22Us
US6987101No1997-12-222017-12-22Us
US7163931No2001-12-202021-12-20Us
US6958326No2001-12-202021-12-20Us
US5798338No1995-07-102015-07-10Us
US6441168No2002-07-302022-07-30Us
US8617597No2010-02-082030-02-08Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00225 mg/mLALOGPS
logP2.36ALOGPS
logP3.37ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity101.68 m3·mol-1ChemAxon
Polarizability41.81 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.6376
P-glycoprotein substrateSubstrate0.6524
P-glycoprotein inhibitor IInhibitor0.6171
P-glycoprotein inhibitor IINon-inhibitor0.6726
Renal organic cation transporterNon-inhibitor0.7005
CYP450 2C9 substrateNon-substrate0.796
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.5534
CYP450 2C9 inhibitorNon-inhibitor0.8665
CYP450 2D6 inhibitorNon-inhibitor0.9336
CYP450 2C19 inhibitorNon-inhibitor0.7754
CYP450 3A4 inhibitorNon-inhibitor0.8355
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8541
Ames testNon AMES toxic0.9163
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.9757
Rat acute toxicity1.9430 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9393
hERG inhibition (predictor II)Non-inhibitor0.8215
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (37.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Spironolactones and derivatives
Alternative Parents
Cyclohexenones / Gamma butyrolactones / Tetrahydrofurans / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Spironolactone / Cyclohexenone / Gamma butyrolactone / Tetrahydrofuran / Cyclic ketone / Lactone / Ketone / Carboxylic acid ester / Oxacycle / Organoheterocyclic compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
3-oxo steroid, 3-oxo Delta(4)-steroid, steroid lactone (CHEBI:50838)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR: Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12. [PubMed:16157482]
  3. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 Oct;54(4):243-51. [PubMed:8922878]
  4. Arias-Loza PA, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J, Jazbutyte V, Neyses L, Ertl G, Fritzemeier KH, Hegele-Hartung C, Pelzer T: Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension. 2006 Nov;48(5):994-1001. Epub 2006 Sep 25. [PubMed:17000933]
  5. Sitruk-Ware R: New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. [PubMed:16291771]
  6. Sitruk-Ware R: New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-83. [PubMed:15493951]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 Oct;54(4):243-51. [PubMed:8922878]
  3. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E: Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995 Jun 12;761:311-35. [PubMed:7625729]
  4. Oelkers WK: Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996 Apr;61(4):166-71. [PubMed:8732994]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Maia H Jr, Casoy J, Athayde C, Valente Filho J, Coutinho EM: The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium. Eur J Contracept Reprod Health Care. 2010 Feb;15(1):35-40. doi: 10.3109/13625180903383928. [PubMed:20063991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Koitka M, Hochel J, Gieschen H, Borchert HH: Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J Pharm Biomed Anal. 2010 Feb 5;51(3):664-78. doi: 10.1016/j.jpba.2009.09.023. Epub 2009 Sep 23. [PubMed:19850433]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Drug created on July 08, 2007 11:03 / Updated on November 09, 2017 02:59